Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endoglin for targeted cancer treatment.
Rosen LS, Gordon MS, Robert F, Matei DE. Rosen LS, et al. Among authors: matei de. Curr Oncol Rep. 2014 Feb;16(2):365. doi: 10.1007/s11912-013-0365-x. Curr Oncol Rep. 2014. PMID: 24445497 Review.
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Gordon MS, et al. Among authors: matei d. J Clin Oncol. 2006 Sep 10;24(26):4324-32. doi: 10.1200/JCO.2005.05.4221. Epub 2006 Aug 8. J Clin Oncol. 2006. PMID: 16896006 Clinical Trial.
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.
Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS. Gordon MS, et al. Clin Cancer Res. 2014 Dec 1;20(23):5918-26. doi: 10.1158/1078-0432.CCR-14-1143. Epub 2014 Sep 26. Clin Cancer Res. 2014. PMID: 25261556 Free PMC article. Clinical Trial.
CD73: an emerging checkpoint for cancer immunotherapy.
Chen S, Wainwright DA, Wu JD, Wan Y, Matei DE, Zhang Y, Zhang B. Chen S, et al. Among authors: matei de. Immunotherapy. 2019 Aug;11(11):983-997. doi: 10.2217/imt-2018-0200. Epub 2019 Jun 21. Immunotherapy. 2019. PMID: 31223045 Free PMC article.
Novel agents in ovarian cancer.
Matei D. Matei D. Expert Opin Investig Drugs. 2007 Aug;16(8):1227-39. doi: 10.1517/13543784.16.8.1227. Expert Opin Investig Drugs. 2007. PMID: 17685871 Review.
138 results